How Much Does RASONQUE Cost?

Published on August 27, 2026 | Written by Alec Pow
This article was researched using 12 sources. See our methodology and corrections policy.

RASONQUE is Revolution Medicines’ newly approved once-daily oral treatment for certain adults with metastatic pancreatic adenocarcinoma. As of August 27, 2026, Revolution Medicines lists a wholesale acquisition cost of $39,800 for a 30-day supply at the recommended daily dose.

That manufacturer figure translates to $119,400 for three 30-day fills, $238,800 for six, and $477,600 for twelve. Those amounts represent list-price arithmetic, not what every patient pays. Commercial insurance, Medicare Part D, manufacturer assistance, formulary rules, and specialty-pharmacy processing can reduce or reshape the patient’s bill.

The useful cost unit is one 30-day prescription. Insurance status, assistance eligibility, treatment duration, prior authorization, and other covered prescriptions are the main modifiers.

How Much Does RASONQUE Cost?

RASONQUE carries a manufacturer list price of $39,800 (at $30 per hour, earning that amount would take about 7.7 months of full-time work, before taxes) per 30 days, but insured patients can face far lower out-of-pocket costs.

Important numbers

• RASONQUE wholesale acquisition cost is $39,800 per 30 days.
• Three fills equal $119,400 at list price.
• Twelve 30-day fills equal $477,600 at list price.
• The 2026 Medicare Part D annual out-of-pocket threshold is $2,100 for covered Part D drugs.

What you’re buying

The $39,800 monthly price 

Revolution Medicines prices RASONQUE at $39,800 (about 7.7 months of full-time work at $30 per hour) for each 30-day supply based on the recommended daily dose. Dividing that figure by 30 gives a list-price equivalent of about $1,326.67 per day. Multiplying the same 30-day figure by 12 produces $477,600 across 360 days. Bloomberg described the launch price as exceeding $475,000 on an annualized basis.

The distinction between annualized price and annual patient spending matters. A person may receive fewer than twelve fills, continue treatment beyond 360 days, start late in a calendar year, change coverage, or stop treatment under the direction of the treating clinician. The manufacturer has not published a fixed number of fills that every patient will receive. The $477,600 figure is arithmetic built from twelve consecutive 30-day supplies, not a guaranteed treatment-course bill.

Commercial insurance

A commercially insured patient should not assume that the pharmacy will request $39,800 (about 7.7 months of full-time work at $30 per hour) at pickup. Managed Healthcare Executive reported on August 26 that eligible commercially insured patients may qualify for $0 copay through Revolution Medicines’ (ON)Path program. Eligibility conditions apply, so that figure should not be treated as a universal patient price.

The same report says company officials expect insurer discounts of roughly 20% to 30%. Applying those percentages to the $39,800 WAC produces payer-level arithmetic of $31,840 after a 20% reduction and $27,860 after a 30% reduction. Those numbers describe possible insurer economics, not the patient’s copay.

A plan could use a fixed copayment, coinsurance, deductible, specialty tier, prior authorization, or another benefit design. Revolution Medicines says its (ON)Path support program can assist with insurance, financial support, and treatment education. An insured patient’s useful question is the approved out-of-pocket amount after the benefit and any permitted assistance are applied.

Medicare Part D

For Medicare beneficiaries, RASONQUE’s manufacturer price and the Part D out-of-pocket amount are two very different figures. CMS sets the 2026 defined-standard Part D deductible at up to $615, with a $2,100 annual out-of-pocket threshold. During initial coverage under the standard benefit, the enrollee pays 25% coinsurance for covered Part D drugs until qualifying out-of-pocket spending reaches that threshold.

After the threshold is reached, the enrollee moves into catastrophic coverage and pays $0 in additional cost sharing for covered Part D drugs for the rest of that calendar year. This does not mean every Medicare patient will personally spend exactly $2,100 on RASONQUE. Spending on other covered drugs may already count toward the threshold, some plans have a lower deductible, and assistance such as Extra Help can change the calculation. RASONQUE is also newly launched, so the patient’s plan must still determine coverage, formulary placement, prior authorization requirements, and permitted specialty pharmacy.

Specialty-pharmacy rules

RASONQUE is not distributed like a common neighborhood-pharmacy prescription. The manufacturer’s professional site says it is available through select oncology-focused specialty pharmacies and identifies 30-count 100 mg and 150 mg tablet packages. The listed pharmacy network includes Biologics by McKesson and Onco360, with MedPlus Specialty Pharmacy serving Puerto Rico.

Onco360 separately confirmed on August 26 that it had been selected as a national RASONQUE pharmacy partner. A specialty pharmacy may verify benefits, obtain insurer approval, coordinate shipment, and connect the patient with support resources before dispensing. Those steps can affect timing even when the list price is already known. A patient can know that one 30-day supply has a WAC of $39,800 and still not know the exact personal payment until the insurer and pharmacy finish processing the prescription.

RASONQUE and chemotherapy

RASONQUE’s drug-acquisition price is unusually visible because the manufacturer has published one 30-day WAC. Chemotherapy often creates several billing categories instead, including drug acquisition, infusion-center charges, administration, laboratory work, supportive medications, imaging, and professional services. ThePricer’s review of chemotherapy costs shows why comparing only the medication price can miss part of the treatment bill.

The FDA approved RASONQUE after a trial comparing daraxonrasib with physician-selected chemotherapy in previously treated metastatic pancreatic cancer. Reuters reported the launch at $39,800 per 30-day supply and noted its oral once-daily format. An oral medicine shifts much of the acquisition expense toward the pharmacy benefit, but it does not erase the rest of oncology care. A price comparison with another high-cost oral cancer medicine such as Revlimid is closer on billing structure than comparing one bottle of RASONQUE with one infusion appointment.

Three patient-payment cases

List-price case

A patient without applicable coverage or assistance faces the published WAC most directly. One 30-day supply carries a $39,800 list price. Three consecutive fills reach $119,400. The primary driver is lack of a benefit or assistance mechanism reducing the pharmacy amount.

Commercial-insurance case

An eligible commercially insured patient could qualify for the manufacturer’s reported $0 copay support. In that case, the patient’s pharmacy payment may bear little resemblance to the drug’s WAC. Eligibility, program limits, insurer approval, and pharmacy processing control the result. The manufacturer or insurer may still exchange much larger sums behind the scenes.

Medicare Part D case

A beneficiary with RASONQUE covered under Part D has a different framework. Covered prescription spending counts toward the 2026 annual $2,100 out-of-pocket threshold, after which catastrophic coverage carries no further enrollee cost sharing for covered Part D drugs. Medicare also offers a Prescription Payment Plan that lets participating enrollees spread eligible out-of-pocket prescription expenses across monthly payments. It changes payment timing rather than reducing the amount owed.

Worked RASONQUE math

Start with the manufacturer WAC of $39,800 per 30 days. One fill is $39,800. Three fills equal $39,800 × 3 = $119,400. Six equal $39,800 × 6 = $238,800. Twelve equal $39,800 × 12 = $477,600. Those figures form one drug-only list-price model before insurance discounts, patient assistance, Medicare rules, or other medical care.

That calculation is useful for comparing manufacturer prices, payer exposure, and gross oncology spending. It is a poor estimate of personal cost for someone whose insurer covers the drug or who qualifies for assistance. A newly diagnosed patient looking at other specialty-cancer drug structures may also compare Anktiva treatment pricing, where acquisition cost and insurance exposure also answer different financial questions.

Makes sense if

• You need the current manufacturer list-price benchmark.
• You are estimating gross spending across several 30-day fills.
• You want to compare oral oncology drug acquisition costs.
• You are separating payer spending from patient spending.

Doesn’t make sense if

• You assume every insured patient pays the full WAC.
• You treat twelve fills as a guaranteed treatment duration.
• You apply an insurer discount directly to a patient’s copay.
• You assume every Part D plan has already approved the new medicine.

What we verified

• Checked the FDA’s August 26 approval announcement for the once-daily oral treatment and approved metastatic pancreatic cancer setting.
• Confirmed the published WAC, launch timing, and U.S. availability through Revolution Medicines’ SEC disclosure and company materials cited above.
• Cross-referenced Medicare patient-liability rules with current CMS and Medicare benefit information cited above.

Article Highlights

• RASONQUE has a list price of $39,800 per 30-day supply.
• Twelve 30-day fills equal $477,600 at WAC.
• Eligible commercially insured patients may qualify for $0 copay support.
• Medicare Part D has a $2,100 annual out-of-pocket threshold for covered drugs in 2026.
• Specialty-pharmacy and prior-authorization rules can affect the first fill.
• List price, insurer cost, and patient out-of-pocket cost are separate measures.

Answers to Common Questions

How much is RASONQUE per month?

Revolution Medicines lists RASONQUE at $39,800 for a 30-day supply at the recommended dose.

How much would a year of RASONQUE cost at list price?

Twelve consecutive 30-day fills equal $477,600. That is a 360-day list-price calculation rather than a guaranteed treatment-course or patient bill.

Can insurance make RASONQUE cheaper?

Yes. Commercial insurance can substantially change the pharmacy payment, and eligible commercially insured patients may qualify for $0 copay support through the manufacturer’s program.

What could a Medicare patient pay for RASONQUE?

If the medicine is covered under the patient’s Part D plan, its cost sharing contributes toward the 2026 annual $2,100 Part D out-of-pocket threshold. Other covered prescriptions and assistance can change how much of that threshold is attributable to RASONQUE.